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Noise sensitivities, i.e. fear, anxiety and phobia based responses to 
noise/sound stimuli (Sherman and Mills 2008), have a high prevalence in dogs: 
Blackwell and others (2013) found that 25% of owners surveyed in the UK 
reported their dog to be fearful of noises, with 49% of owners in the same study 
indicating that their dog displays at least one sign of fear when exposed to loud 
noises, which is consistent with the 42% reported in the 2015 PDSA Paw report 
(PDSA 2015). The most commonly reported noise stimulus triggering a 
response in these studies is fireworks, but this problem is more than a seasonal 
issue with dogs commonly reacting to a range of other noises such as thunder, 
gunshots, vehicle and household noises, by showing signs including panting, 
escape attempts, hiding and destructiveness (Sherman and Mills 2008).  
Despite there being well-established treatment programmes for the long-term 
elimination of the problem (Levine and others 2007), it is a cause for concern 
that less than a third of owners have sought help for their dog, and the majority 
of those who do, turn to someone other than their veterinarian (Blackwell and 
others 2013) suggesting that a large number of dogs remain untreated for noise 
sensitivities. Underlying medical problems reported to be associated with the 
onset of a noise sensitivity in dogs include cognitive dysfunction (Landsberg 
and others 2011), suboptimal thyroid function (Aronson and Dodds 2005; 
Dodman and others 2013) and, based on our own experience, a range of pain-
related problems. The veterinary profession should be at the forefront of actively 
promoting the potential to solve the problem of noise sensitivities in dogs. 
Long term management involves desensitising the dog to the fear-provoking 
noise over an extended time period and although time consuming has an 
excellent prognosis with the right treatment programme; over 90% of owners 
completing an 8 week training programme using AdaptilTM pheromone diffuser 
alongside a sound CD reported improvement (Levine and others 2007). One of 
the CDs was the Sounds ScaryTM programme, now available free of charge 
from https://www.dogstrust.org.uk/help-advice/dog-behaviour-health/sound-
therapy-for-pets . 
Many owners will try to avoid or minimise the impact of the problem by, e.g. 
walking in daylight hours, shutting windows/doors, playing the 
radio/television/music to mask the noise. If the problem is severe, then they 
may seek help from their vet, but often shortly before noise exposure e.g. Guy 
Fawkes Night or New Year’s Eve. In this situation there is no time to implement 
effective training to desensitise the dog and so there is a need for short term 
management interventions that will help reduce the dog’s suffering at this time.  
In these circumstances there is undoubtedly a role for short acting medication 
with a rapid onset that alleviates the fear and anxiety in the short term. The use 
of benzodiazepines e.g. alprazolam (Crowell-Davis and others 2003), and 
diazepam (Herron and others 2008), and the alpha-2 adrenergic receptor 
agonist clonidine (Ogata and Dodman 2011) have been recommended for 
treatment, but these are not licensed, and their efficacy in our experience is 
quite variable. In the current issue of the Veterinary Record, Korpivaara and 
others (2017) examine the efficacy of a new licensed formulation of the alpha-2 
adrenoreceptor agonist dexmedetomidine administered at 0.1mg/ml as an 
oromucosal gel against a placebo in alleviating clinical signs of anxiety and fear 
associated with fireworks in dogs. A higher proportion of dogs were reported by 
their owners as having an excellent or good overall treatment effect (compared 
to what they recalled from the previous year) in the dexmedetomidine 
oromucosal gel group (72%) compared to the placebo group (37%). In addition, 
owners were asked to score clinical signs and extent of anxiety and fear on a 
scale of 12 behavioural signs: panting, trembling, vocalising, pacing and house 
soiling were 5 of the 12 behavioural signs found to be significantly lower 
(suggesting less distress) in the dexmedetomidine group when compared to the 
placebo group. Owners assessed functional alertness by calling their dog and 
scoring their observations (related to responsiveness and ability to stand and 
walk) with >85% of dogs being classed as fully functional with no apparent 
differences between groups demonstrating that dexmedetomidine appeared to 
be at a sub-sedative dose for the majority of dogs.   
Studies like these are important because they provide the veterinary field with a 
stronger evidence base for new potential products in a market that has a wealth 
of largely untested supplements and suggestions, which may be far less useful. 
Indeed as noted in this study and elsewhere (Cracknell and Mills 2008), there is 
a large placebo effect to many treatments for behaviour problems, and so 
veterinarians need to be careful not to be seduced by untested alternatives. 
They also need to comply with the prescription cascade when considering the 
use of medication, and so need to be aware that dexmedetomidine oromucosal 
gel (SileoTM, Zoetis) is currently the only product approved by the European 
Medicinal Agency and Food and Drug Administration for treating canine noise 
aversion associated with fear and anxiety.  
The study also highlights the value of finding better ways of administering 
effective treatments to ensure what works in theory also works in practice. The 
gel is applied onto the oral mucosa of the dog's cheek and the vast majority of 
owners (84.6%) found the product easy to administer. However it is worth 
noting that in dogs that are not accustomed to handling procedures 
administration has been reported to be more difficult and so there is in an 
important role for the veterinary team to give advice on how to teach a dog to 
accept such handling.   
However, it is important for veterinarians to recognise that their responsibility 
does not end with the dispensing of medication. It is important that the 
veterinary team is pro-active in following up such cases when the event is over, 
to ensure that the long term problem and root cause of the issue is addressed. 
Out of season group desensitisation classes are an efficient way of helping and 
caring for a large number of clients, who can be taught through the principles of 
a generic programme and form a support group to aid motivation (Sherman and 
Mills 2008). Many veterinarians feel ill-prepared to manage behaviour problems 
in practice (Roshier and McBride 2013) but they do not need to have specialist 
training to offer a professional service when it comes to managing noise fears. 
As veterinarians, they need to evaluate the health of the animal and ensure the 
problem is not associated with some underlying medical problem; they are also 
responsible for any medication they prescribe and need to understand the 
indications and contraindications and when (and to whom) to refer for specialist 
help, but other members of the team can take on the wider client education and 
training roles, and many will do so enthusiastically. In this way all will benefit.  
This new product may also have a wider range of applications for which there is 
currently no licensed product. This includes other situationally occurring fears 
and anxieties such as fear of the veterinary clinic and associated handling (see 
papers by Hopfensperger and others (2013) and Cohen and Bennett (2015) 
who used oromucosal detomidine gel and dexmedetomidine injectable 
administered orotransmucosally respectively, to facilitate handling of dogs in the 
veterinary context at sedative doses). 
In the authors’ experience, many dogs with fear of fireworks develop an overall 
increase in anxiety around the time of year with some dogs not wanting to leave 
the house despite no audible fireworks. In addition owners also report mood 
changes that are most likely due to repeat exposure to anxiogenic stimuli and/or 
anticipation of noises occurring. For other dogs, noise sensitivity to fireworks 
may represent only one of many noises which trigger fear and anxiety all year 
round, and can be only one of several expressions of an underlying 
fearful/anxious temperament, such as social fears/anxieties, separation related 
problems and generalised anxiety disorders. The optimum treatment of such 
cases may differ to those acute and occasional noise fears, and may include 
the use of long term psychoactive medication e.g. clomipramine (Crowell-Davis 
and others 2003) or fluoxetine (Ibáñez and Anzola 2009) potentially alongside a 
short acting anxiolytic, such as dexmedetomidine or a benzodiazepine as 
needed, and this combination should be safe, assuming the animal is in good 
physical health. 
Medication(s) chosen should always be tailored to the individual based on a 
thorough review of the behavioural history (screening for concurrent fears and 
anxieties) and medical history (screen for underlying disease, potential drug 
interactions or contraindications) and should always be provided alongside 
management advice and a behaviour modification program that is feasible for 
both the patients and their caretaker within the daily constraints of everyday life.  
 
In conclusion, dexmedetomidine gel, provides an important part of the arsenal 
of any welfare centred practice and extends the opportunity for veterinarians to 
more fully engage with the prevalent welfare problem of noise sensitivity.   
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